Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13125MR)

This product GTTS-WQ13125MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13125MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2605MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ1644MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ1504MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ1955MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ5368MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ12175MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ6540MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ13355MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW